A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Trial Profile

A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 01 Sep 2017

At a glance

  • Drugs Cyclophosphamide (Primary) ; Fludarabine (Primary) ; NY-ESO-1c259 TCR-transduced lymphocytes (Primary)
  • Indications Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Sponsors Adaptimmune
  • Most Recent Events

    • 10 Jun 2017 Biomarkers information updated
    • 06 Jun 2017 Results (n=34) presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2017 According to an Adaptimmune media release, updated results from the study were presented at the the 2017 ASCO annual meeting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top